MetaStat (MetaStat) Risk Assessment

View and export this data going back to 2008. Start your Free Trial

What is MetaStat Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of MetaStat is: No Data: Cannot be evaluated.

Competitive Comparison of MetaStat's Risk Assessment

For the Biotechnology subindustry, MetaStat's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

MetaStat's Risk Assessment Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MetaStat's Risk Assessment distribution charts can be found below:

* The bar in red indicates where MetaStat's Risk Assessment falls into.

MetaStat (OTCPK:MTST) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

MetaStat Risk Assessment Related Terms

Thank you for viewing the detailed overview of MetaStat's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

MetaStat (MetaStat) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MetaStat Inc (OTCPK:MTST) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

N/A

Address

27 Drydock Avenue, 2nd Floor, Boston, MA, USA, 02210

Website

http://www.metastat.com

MetaStat Inc is a US-based biotechnology company which focuses on discovering and developing personalized therapeutic (Rx) and diagnostic (Dx) treatment solutions for cancer patients. The company focuses on development programs of the novel therapeutic product candidates that target the Mena protein isoform whereas the Companion Diagnostics program is focused on developing companion tests to be used in combination with cancer drugs, that provide essential information for the safe and effective use of a corresponding drug or biological product to improve patient outcome. It also develops a prognostic diagnostic program which is focused on developing diagnostic tests that predict the risk of future metastasis in cancer patients following the initial treatment of their primary tumor.

Executives

Daniel H Schneiderman	officer: VP OF FINANCE AND SECRETARY	760 PARKSIDE AVE. SUITE 304, SUITE 207, BROOKLYN NY 11226
Jerome B Zeldis	director	8767 E. VIA DE VENTURA, SUITE 190, SCOTTSDALE AZ 85258
Paul Billings	director	11055 FLINTKOTE AVENUE, SUITE B, SAN DIEGO CA 92121
Richard J Berman	director	305 COLLEGE ROAD EAST, PRINCETON NJ 08540
Martin J Driscoll	director	C/O JAVELIN PHARMACEUTICALS, INC., 125 CAMBRIDGE PARK DRIVE, CAMBRIDGE MA 02140
Oscar Bronsther	director	4 AUTUMNWOOD COURT, THE WOODLANDS TX 77380
Johan M. Spoor	director	500 BOYLSTON STREET, SUITE 1600, BOSTON MA 02116
David N Siegel	director	T-S CAPITAL PARTNERS, LLC, 1350 TREAT BOULEVARD, SUITE 400, WALNUT CREEK CA 94597
Warren C Lau	director	2635 N. CRESCENT RIDGE DRIVE, THE WOODLANDS TX 77381
Patrick T Mooney	director	C/O SONTRA MEDICAL CORPORATION, 10 FORGE PARKWAY, FRANKLIN MA 02038
David M. Epstein	director	OSI PHARMACEUTICALS, INC., 41 PINELAWN ROAD, MELVILLE NY 11747
Richard W Perkins	10 percent owner	730 EAST LAKE STREET, WAYZATA MN 55391
Harvey Judkowitz	director	10220 SW 124 ST, MIAMI FL 33176

MetaStat (MetaStat) Headlines

No Headlines